Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
55M
-
Shares change
-
+55M
-
Total reported value, excl. options
-
$1.47B
-
Value change
-
+$1.47B
-
Number of buys
-
78
-
Price
-
$26.93
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q4 2018
80 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q4 2018.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55M shares
of 226M outstanding shares and own 24.31% of the company stock.
Largest 10 shareholders include TPG Group Holdings (SBS) Advisors, Inc. (23.1M shares), FMR LLC (4.91M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.51M shares), Capital Research Global Investors (2.51M shares), Capital World Investors (2.17M shares), BlackRock Inc. (2.08M shares), Vanguard Group Inc (2.05M shares), Capital International Investors (2.03M shares), PERCEPTIVE ADVISORS LLC (1.54M shares), and ALLIANCEBERNSTEIN L.P. (1.29M shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.